What is the difference between an antibody and an antigen?

An antigen is a foreign substance, typically a piece of a virus or bacteria, that triggers an immune response. An antibody is a protein produced by B cells that specifically recognizes and binds to an antigen, helping to neutralize or eliminate the pathogen.

How quickly do B cells develop optimal antibodies after initial exposure?

B cells begin replicating and evolving their receptors within hours of infection. This process of 'affinity maturation' leads to increasingly effective antibodies, with neutralizing antibodies typically appearing within one to two weeks after a new viral infection.

Does a positive antibody test (IgG/IgM) guarantee immunity to SARS-CoV-2?

A positive IgG or IgM test indicates exposure to the virus and antibody production, but it does not guarantee effective immunity. Many antibodies may bind to the virus without neutralizing it, meaning they don't stop it from infecting cells. Specialized neutralization assays are required to determine truly protective antibodies.

What is the primary function of cytotoxic T-cells (CD8 T-cells)?

Cytotoxic T-cells (CD8 T-cells) are powerful immune cells that specialize in recognizing and killing virus-infected cells. They identify infected cells by detecting viral protein fragments presented on the cell surface via MHC molecules, effectively shutting down 'virus factories' before significant viral replication occurs.

Why has a vaccine for HIV proven so difficult to develop?

HIV's high mutation rate and chronic nature lead to enormous viral variability, making it difficult for the immune system or vaccines to target consistently. Additionally, the virus's envelope protein is covered in a sugar shield, making it challenging for antibodies to bind to critical regions required for neutralization.

How do repurposed drugs like AZT and Truvada contribute to HIV management?

AZT was an early repurposed drug that helped reduce viral loads but was eventually escaped by HIV. Truvada is used in pre-exposure prophylaxis (PrEP), where daily intake can prevent new HIV infections by stopping the virus from replicating, demonstrating that non-vaccine solutions can effectively manage epidemics.

How does the estimated severity of SARS-CoV-2 compare to seasonal flu?

While initial predictions varied, SARS-CoV-2 is considered to be significantly worse than seasonal flu, an estimated 5 to 10 times more deadly, especially for individuals with pre-existing conditions like diabetes and obesity. Its global economic impact also far exceeds that of a typical flu season.

What are monoclonal antibodies and how can they treat or prevent COVID-19?

Monoclonal antibodies are laboratory-produced antibodies that mimic the body's natural immune response. They can be engineered to specifically target and neutralize viruses like SARS-CoV-2. They offer a promising approach for both preventing infection (especially in high-risk groups) and treating active disease, similar to how they've been used for Ebola.

What is the difference between an attenuated and an inactivated vaccine?

An attenuated vaccine uses a weakened but live form of the virus (e.g., yellow fever, measles), allowing it to replicate without causing severe disease to elicit a strong immune response. An inactivated vaccine uses a killed version of the virus (e.g., polio, hepatitis A), which cannot replicate but still exposes the immune system to its antigens.

What is the realistic goal for a SARS-CoV-2 vaccine regarding immunity?

The primary goal for a SARS-CoV-2 vaccine isn't necessarily sterilizing immunity (complete prevention of infection), but rather to significantly reduce the viral load upon exposure. This reduction would decrease symptoms, prevent severe disease (e.g., ICU admission), and lower transmission rates, making it an effective public health tool.

Key Moments

#115–David Watkins, PhD: Immunology, monoclonal antibodies, & vaccine strategies for COVID-19

Peter Attia MD

People & Blogs4 min read98 min video

Jul 9, 2020|3,428 views|61|7

masterclass

Save to Pod

Key Moments

TL;DR

Immunology explained: innate vs. adaptive, B/T cells, antibodies, and vaccine strategies for COVID-19.

Key Insights

The adaptive immune system, with its T and B cells, evolved before amphibians and is the basis for vaccination.

Antibodies are proteins that bind to antigens; neutralizing antibodies are crucial as they block viral entry into cells.

Standard antibody tests (IgG, IgM) measure total antibodies, not necessarily neutralizing ones, highlighting variability in immune response.

Cytotoxic T cells (CD8 T cells) are vital for destroying virus-infected cells, acting as a critical defense mechanism.

While vaccines aim for durable immunity, challenges like viral mutation (e.g., HIV, Hepatitis C) necessitate diverse approaches, including drugs and monoclonal antibodies.

Monoclonal antibodies, cloned from elite responders, offer a promising strategy for both preventing and treating infections, particularly for high-risk individuals.

THE EVOLUTION OF IMMUNE DEFENSE

The human immune system is broadly divided into innate and adaptive responses. The innate system provides immediate, non-specific defense, while the adaptive system, characterized by T and B cells, offers a highly specific and memory-driven defense. This adaptive immunity, which evolved well before amphibians, is the cornerstone of vaccination, a public health measure that has saved countless lives.

THE MECHANISMS OF ADAPTIVE IMMUNITY

The adaptive immune system has two primary arms: cellular and humoral. The humoral response, mediated by B cells, involves the production of antibodies. When a virus enters the body, B cells recognize viral antigens and undergo a process of affinity maturation, replicating and mutating to produce antibodies that bind tightly to the virus. These antibodies can neutralize the virus by preventing it from infecting host cells.

UNDERSTANDING ANTIBODIES AND NEUTRALIZATION

Antigens are essentially pieces of a virus that trigger an immune response. Antibodies are proteins produced by B cells that bind to these antigens. Not all antibodies are equally effective; neutralizing antibodies are critical because they bind to specific regions of a virus (like the spike protein of SARS-CoV-2) that are essential for cell entry, thereby blocking infection. Standard antibody tests often measure total antibody levels (IgG, IgM) but do not distinguish between neutralizing and non-neutralizing antibodies.

THE ROLE OF T CELLS AND CYTOTOXIC KILLERS

Complementing the humoral response are T cells, particularly cytotoxic T lymphocytes (CTLs or CD8 T cells). These cells are responsible for identifying and destroying infected host cells, effectively shutting down 'virus factories' before they can release more viral particles. CD8 T cells recognize viral fragments presented on the surface of infected cells via MHC molecules, providing a crucial mechanism for clearing infections, especially those like HIV where the virus hides within cells.

CHALLENGES IN VIRAL IMMUNITY AND VACCINE DEVELOPMENT

Viruses like HIV and Hepatitis C present significant challenges due to their high mutation rates and ability to evade immune responses. Developing effective vaccines against such viruses is difficult because they can rapidly evolve escape mechanisms. While traditional vaccines rely on eliciting strong neutralizing antibody responses, the complexity of some viruses necessitates exploring alternative or complementary strategies.

MONOCLONAL ANTIBODIES: A PROMISING THERAPEUTIC AVENUE

Monoclonal antibodies, which are laboratory-produced antibodies cloned from the B cells of elite responders, offer a powerful therapeutic tool. These antibodies can be engineered to provide specific and potent neutralization of viruses. They can be used for both prevention and treatment, providing a direct infusion of immune protection. This approach is particularly promising for high-risk populations or when vaccine-induced immunity might be less robust, such as in the elderly.

VACCINE STRATEGIES FOR CORONAVIRUS

Current efforts for a coronavirus vaccine are exploring various strategies, including mRNA, DNA, and spike protein-based vaccines, moving beyond traditional inactivated or attenuated virus approaches. The goal is not necessarily sterilizing immunity but rather reducing viral load, preventing severe disease, and decreasing transmission. The effectiveness of these vaccines will ultimately be determined by their ability to induce durable neutralizing antibody responses in humans.

LEARNING FROM PAST PANDEMICS

The lessons learned from past viral epidemics like HIV and Zika are invaluable. The development of highly active antiretroviral therapy (HAART) transformed HIV from a uniformly fatal disease into a chronic manageable condition. Similarly, the development of curative drugs for Hepatitis C, despite the lack of a vaccine, highlights the power of pharmaceutical innovation. These experiences inform our approach to the current coronavirus pandemic, emphasizing the need for diverse strategies and a rapid scientific response.

THE FUTURE OF INFECTIOUS DISEASE INTERVENTION

The scientific community is employing a 'try everything' approach to combat infectious diseases. This includes not only traditional vaccine development but also the exploration of therapeutic drugs and monoclonal antibodies. The goal is to create a combination of interventions that can effectively control viral spread and mitigate disease severity. The development of monoclonal antibodies, cloned from individuals with exceptional immune responses, represents a new frontier in preventing and treating infectious diseases.

Mentioned in This Episode

●Products

●Companies

●Organizations

●Books

●Concepts

●People Referenced

Common Questions

The immune system is divided into two primary branches: the innate immune system, which provides immediate, non-specific defense, and the adaptive immune system, which offers a targeted, memory-based response. The adaptive system further bifurcates into cellular (T-cells) and humoral (B-cells) responses.

Topics

Immune System Vaccine Development Medicine & Clinical Adaptive Immunity Innate Immunity B Cell Response T Cell Response Neutralizing Antibodies HIV Vaccine Hepatitis C Treatment Monoclonal Antibodies

Mentioned in this video

People

David Watkins

Professor of pathology at George Washington University Medical School, previously at the University of Miami, with expertise in immunology, particularly SIV and HIV.

Raymond Schinazi

A PhD biochemist at Emory University who discovered several drugs, including the first two drugs that later cured Hepatitis C.

Anthony Fauci

An individual working at Harvard's primate center in the early days of the HIV epidemic who isolated the first simian immunodeficiency virus.

Myrna Bonaldo

A colleague based in Fiocruz, Rio, who collaborated with Dr. Watkins on a study of the 17D yellow fever vaccine's immune response.

Dennis Burton

A pioneer researcher at Scripps who was instrumental in developing techniques to isolate and clone broadly neutralizing antibodies against HIV.

Organizations

American Academy of Microbiology

An academy which Dr. Watkins was elected a fellow of.

Scripps Research Institute

The institution where Dennis Burton works, contributing to research on broadly neutralizing antibodies.

Oxford University

Mentioned for their approach to a COVID-19 vaccine, using a chimpanzee adenovirus to express the spike protein.

George Washington University Medical School

The institution where Dr. David Watkins recently relocated as a professor of pathology.

Emory University

The institution where Raymond Schinazi worked when he discovered key drugs for HIV and Hepatitis C.

University of Miami

Where Dr. Watkins previously worked for 10 years, serving as vice chair of research in pathology.

Rockefeller University

A university where a study on coronavirus neutralizing antibodies was conducted, observing significant variability in human responses.

Fiocruz

A research institution in Rio where Myrna Bonaldo, a collaborator of Dr. Watkins, is based.

Drugs & Medications

HIV

Human Immunodeficiency Virus, a chronic virus that Dr. Watkins has extensively studied, noting its rapid evolution and challenges for vaccine development.

Highly Active Antiretroviral Therapy

A game-changing drug development in the mid-90s that transformed HIV from a uniformly fatal disease into a chronic manageable condition.

Truvada

A drug used in Pre-exposure prophylaxis (PrEP) to prevent HIV infection.

Ebola virus

A virus for which simple injections of monoclonal antibodies after infection significantly dropped the death rate.

Dengue virus

A tropical disease virus that Dr. Watkins studies.

Zika virus

A tropical disease virus that Dr. Watkins studied, particularly its impact on pregnant women and the use of monoclonal antibodies for prevention.

AZT

One of the earliest repurposed drugs used against HIV, which initially reduced viral loads but was eventually escaped by the virus.

Measles, Mumps, and Rubella (MMR) vaccine

Mentioned as an example of a live attenuated virus vaccine, similar in concept to the yellow fever vaccine.

Hepatitis C Virus

A virus that replicates to enormous levels with high variability, for which a vaccine is difficult but has been cured by newly developed drugs.

Pre-exposure prophylaxis

A strategy where individuals take a daily drug like Truvada to prevent HIV infection, which has been groundbreaking in curbing new infections.

Companies

Brazil

A country in South America that Dr. Watkins has fallen in love with and where he studies many tropical diseases.

Pfizer

Mentioned as one of the companies involved in the development of COVID-19 vaccines, likely focusing on newer approaches like mRNA.

Moderna

Mentioned as a company involved in COVID-19 vaccine development, likely using mRNA technology.

Locations

São Paulo

A city in Brazil where Peter Atia planned to take his family, and where Dr. Watkins's colleague Espas Callas manages yellow fever patients.

Concepts

ACE2 Receptor

The receptor on human cells that SARS-CoV-2 binds to for entry, a key target for neutralizing antibodies.

Simian Immunodeficiency Virus

A non-human primate virus that serves as an animal model for HIV, studied by Dr. Watkins.

SARS-CoV-2

The coronavirus discussed in the context of its immunology, vaccine strategies, and comparison to other viruses.

Studies & Research

New England Journal of Medicine

A medical journal that published a paper on cancer treatment using antibodies to reactivate T-cells, leading to tumor eradication.

Products

17D Yellow Fever Vaccine

An attenuated yellow fever vaccine derived from a weakened virus, known for its high efficacy in inducing neutralizing antibodies.

Supplements

Humira

One of the most prescribed monoclonal antibody drugs today, used as an example of the feasibility and importance of monoclonal antibodies in modern medicine.